Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2024

Open Access 01-12-2024 | Hypertension | Research

Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data

Authors: Rosalynn R.Z. Conic, Terrie Vasilopoulos, Karthik Devulapally, Rene Przkora, Andrew Dubin, Kimberly T. Sibille, Aaron D. Mickle

Published in: BMC Urology | Issue 1/2024

Login to get access

Abstract

Background

Urologic chronic pelvic pain syndrome (UCPPS), which includes interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis (CP/CPPS), is associated with increased voiding frequency, nocturia, and chronic pelvic pain. The cause of these diseases is unknown and likely involves many different mechanisms. Dysregulated renin-angiotensin-aldosterone-system (RAAS) signaling is a potential pathologic mechanism for IC/BPS and CP/CPPS. Many angiotensin receptor downstream signaling factors, including oxidative stress, fibrosis, mast cell recruitment, and increased inflammatory mediators, are present in the bladders of IC/BPS patients and prostates of CP/CPPS patients. Therefore, we aimed to test the hypothesis that UCPPS patients have dysregulated angiotensin signaling, resulting in increased hypertension compared to controls. Secondly, we evaluated symptom severity in patients with and without hypertension and antihypertensive medication use.

Methods

Data from UCPPS patients (n = 424), fibromyalgia or irritable bowel syndrome (positive controls, n = 200), and healthy controls (n = 415) were obtained from the NIDDK Multidisciplinary Approach to the Study of Chronic Pelvic Pain I (MAPP-I). Diagnosis of hypertension, current antihypertensive medications, pain severity, and urinary symptom severity were analyzed using chi-square test and t-test.

Results

The combination of diagnosis and antihypertensive medications use was highest in the UCPPS group (n = 74, 18%), followed by positive (n = 34, 17%) and healthy controls (n = 48, 12%, p = 0.04). There were no differences in symptom severity based on hypertension in UCPPS and CP/CPPS; however, IC/BPS had worse ICSI (p = 0.031), AUA-SI (p = 0.04), and BPI pain severity (0.02). Patients (n = 7) with a hypertension diagnosis not on antihypertensive medications reported the greatest severity of pain and urinary symptoms.

Conclusion

This pattern of findings suggests that there may be a relationship between hypertension and UCPPS. Treating hypertension among these patients may result in reduced pain and symptom severity. Further investigation on the relationship between hypertension, antihypertensive medication use, and UCPPS and the role of angiotensin signaling in UCPPS conditions is needed.
Appendix
Available only for authorised users
Literature
1.
Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokhoven A, Ellingson BM, Harte SE, Kutch JJ, Lai HH, Martucci KT, et al. Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network. Nat Rev Urol. 2019;16(3):187–200.PubMedPubMedCentralCrossRef
2.
Condorelli RA, Russo GI, Calogero AE, Morgia G, La Vignera S. Chronic prostatitis and its detrimental impact on sperm parameters: a systematic review and meta-analysis. J Endocrinol Invest. 2017;40(11):1209–18.PubMedCrossRef
3.
Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, Gontero P, Gavazzi A, Giubilei G, Prezioso D, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–5. discussion 2415.PubMedCrossRef
4.
Pontari MA, McNaughton-Collins M, O’Leary MP, Calhoun EA, Jang T, Kusek JW, Landis JR, Knauss J, Litwin MS. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005;96(4):559–65.PubMedCrossRef
5.
Huang X, Qin Z, Cui H, Chen J, Liu T, Zhu Y, Yuan S. Psychological factors and pain catastrophizing in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a meta-analysis. Transl Androl Urol. 2020;9(2):485–93.PubMedPubMedCentralCrossRef
6.
Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.PubMedCrossRef
7.
8.
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.PubMedPubMedCentralCrossRef
9.
Anger JT, Dallas KB, Bresee C, De Hoedt AM, Barbour KE, Hoggatt KJ, Goodman MT, Kim J, Freedland SJ. National prevalence of IC/BPS in women and men utilizing veterans health administration data. Front Pain Res (Lausanne). 2022;3:925834.PubMedCrossRef
10.
Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med. 2000;161(6):1999–2004.PubMedCrossRef
11.
Weaver-Osterholtz D, Reams G, Wu Z, Knaus J, Campbell F, Bauer JH. The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors. Am J Kidney Dis. 1996;28(4):603–9.PubMedCrossRef
12.
Lindberg BF, Nilsson LG, Hedlund H, Stahl M, Andersson KE. Angiotensin-I is converted to Angiotensin-Ii by a serine-protease in human detrusor smooth-muscle. Am J Physiol. 1994;266(6):R1861–7.PubMed
13.
Cheng EY, Decker RS, Lee C. Role of angiotensin II in bladder smooth muscle growth and function. Adv Exp Med Biol. 1999;462:183–91.PubMedCrossRef
14.
Comiter CV, Sullivan MP, Yalla SV, Kifor I. Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int J Impot Res. 1997;9(3):135–40.PubMedCrossRef
15.
Aikawa K, Sakai T, Ishibashi K, Shiomi H, Sagawa K, Kumagai S, Kataoka M, Akaihata H, Yamaguchi O. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder. Int J Urol. 2012;19(5):457–64.PubMedCrossRef
16.
Hadzhibozheva P, Tolekova A, Kalfin R, Georgiev T. Analysis of angiotensin II-Induced rat urinary bladder contractions in the presence of angiotensin II receptors blockers. Arch Physiol Biochem. 2021;127(1):1–5.PubMedCrossRef
17.
Lim I, Mitsui R, Kameda M, Sellers DJ, Chess-Williams R, Hashitani H. Comparative effects of angiotensin II on the contractility of muscularis mucosae and detrusor in the pig urinary bladder. Neurourol Urodyn. 2021;40(1):102–11.PubMedCrossRef
18.
Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47–55.PubMedCrossRef
19.
Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology. 2010;57(3):371–83.PubMedCrossRef
20.
Kim A, Han JY, Ryu CM, Yu HY, Lee S, Kim Y, Jeong SU, Cho YM, Shin DM, Choo MS. Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology. 2017;71(3):415–24.PubMedCrossRef
21.
Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112(3):668–76.PubMedCrossRef
22.
Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101(37):13607–12.PubMedPubMedCentralCrossRef
23.
Ener K, Keske M, Aldemir M, Ozcan MF, Okulu E, Ozayar A, Ergin M, Doluoglu OG, Cakmak S, Erel O. Evaluation of oxidative stress status and antioxidant capacity in patients with painful bladder syndrome/interstitial cystitis: preliminary results of a randomised study. Int Urol Nephrol. 2015;47(8):1297–302.PubMedCrossRef
24.
Ehren I, Hosseini A, Lundberg JO, Wiklund NP. Nitric oxide: a useful gas in the detection of lower urinary tract inflammation. J Urol. 1999;162(2):327–9.PubMedCrossRef
25.
Bae WJ, Ha US, Kim S, Kim SJ, Hong SH, Lee JY, Hwang TK, Hwang SY, Kim HJ, Kim SW. Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystitis. Neurourol Urodyn. 2015;34(1):86–91.PubMedCrossRef
26.
Zeybek A, Saglam B, Cikler E, Cetinel S, Ercan F, Sener G. Taurine ameliorates stress-induced degeneration of the urinary bladder. Acta Histochem. 2007;109(3):208–14.PubMedCrossRef
27.
Zhang QH, Zhou ZS, Lu GS, Song B, Guo JX. Melatonin improves bladder symptoms and may ameliorate bladder damage via increasing HO-1 in rats. Inflammation. 2013;36(3):651–7.PubMedCrossRef
28.
Bazi T, Hajj-Hussein IA, Awwad J, Shams A, Hijaz M, Jurjus A. A modulating effect of epigallocatechin gallate (EGCG), a tea catechin, on the bladder of rats exposed to water avoidance stress. Neurourol Urodyn. 2013;32(3):287–92.PubMedCrossRef
29.
de Oliveira MG, Calmasini FB, Alexandre EC, De Nucci G, Monica FZ, Antunes E. Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. Am J Physiol Renal Physiol. 2016;311(1):F85–93.PubMedCrossRef
30.
Birder LA, Wolf-Johnston A, Buffington CA, Roppolo JR, de Groat WC, Kanai AJ. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. J Urol. 2005;173(2):625–9.PubMedCrossRef
31.
32.
Dagher A, Curatolo A, Sachdev M, Stephens AJ, Mullins C, Landis JR, van Bokhoven A, El-Hayek A, Froehlich JW, Briscoe AC, et al. Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the study of Chronic Pelvic Pain (MAPP) Research Network. BJU Int. 2017;120(1):130–42.PubMedPubMedCentralCrossRef
33.
Xu S, Wang X, Wang Y, Lutgendorf S, Bradley C, Schrepf A, Kreder K, O’Donnell M, Luo Y. Transgenic mice expressing MCP-1 by the Urothelium demonstrate bladder hypersensitivity, Pelvic Pain and Voiding Dysfunction: a Multidisciplinary Approach to the study of Chronic Pelvic Pain Research Network Animal Model Study. PLoS ONE. 2016;11(9):e0163829.PubMedPubMedCentralCrossRef
34.
Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y, Nishizawa O. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–12.PubMedCrossRef
35.
Bosch PC. Examination of the significant placebo effect in the treatment of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(2):321–6.PubMedCrossRef
36.
Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1):20–7.PubMedCrossRef
37.
Kim A, Yu HY, Lim J, Ryu CM, Kim YH, Heo J, Han JY, Lee S, Bae YS, Kim JY, et al. Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome. Sci Rep. 2017;7(1):8872.PubMedPubMedCentralCrossRef
38.
Song M, Lim J, Yu HY, Park J, Chun JY, Jeong J, Heo J, Kang H, Kim Y, Cho YM, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.PubMedPubMedCentralCrossRef
39.
Choi D, Han JY, Shin JH, Ryu CM, Yu HY, Kim A, Lee S, Lim J, Shin DM, Choo MS. Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. Sci Rep. 2018;8(1):9782.PubMedPubMedCentralCrossRef
40.
Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, Heo J, Lee S, Shin DM, Choo MS. N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model. Sci Rep. 2019;9(1):8134.PubMedPubMedCentralCrossRef
41.
Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. J Urol. 1992;148(6):1951–6.PubMedCrossRef
42.
Jiang HM, Wang HX, Yang H, Zeng XJ, Tang CS, Du J, Li HH. Role for granulocyte colony stimulating factor in angiotensin II-induced neutrophil recruitment and cardiac fibrosis in mice. Am J Hypertens. 2013;26(10):1224–33.PubMedCrossRef
43.
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34(4 Pt 1):745–50.PubMedCrossRef
44.
Macconi D, Remuzzi G, Benigni A. Key fibrogenic mediators: old players. Renin-angiotensin system. Kidney Int Suppl (2011) 2014, 4(1):58–64.
45.
Landis R. Multidisciplinary Approach to the study of Pelvic Pain (V4) [Dataset]. In.: NIDDK Central Repository; 2023.
46.
47.
O’Leary MP, Sant GR, Fowler FJ Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58–63.PubMedCrossRef
48.
Madsen FA, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am. 1995;22(2):291–8.PubMedCrossRef
49.
Clemens JQ, Calhoun EA, Litwin MS, McNaughton-Collins M, Kusek JW, Crowley EM, Landis JR. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009;74(5):983–7. quiz 987 e981-983.PubMedCrossRef
50.
Cleeland CS, Ryan KM. Pain assessment: global use of the brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.PubMed
51.
Zhang R, Sutcliffe S, Giovannucci E, Willett WC, Platz EA, Rosner BA, Dimitrakoff JD, Wu K. Lifestyle and risk of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a cohort of United States Male Health professionals. J Urol. 2015;194(5):1295–300.PubMedPubMedCentralCrossRef
52.
Wang Y, He L, Zhou Z, Jin L, Meng J, Sun G, Na Y. The association between metabolic syndrome and the National institutes of Health Chronic Prostatitis Symptom Index: results from 1673 men in China. Urology. 2013;82(5):1103–7.PubMedCrossRef
53.
Chung SD, Lin HC. Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS ONE. 2013;8(5):e64630.PubMedPubMedCentralCrossRef
54.
Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is Associated with bladder Pain Syndrome/Interstitial cystitis: a Population-based case-control study. Urol Int. 2015;95(2):227–32.PubMedCrossRef
55.
56.
Peng L, Di XP, He SX, Zeng X, Shen H, Zhu HL, Luo DY. Metabolic syndrome in women with and without interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2020;32(5):1299–306.PubMedCrossRef
57.
Chen HM, Lin CC, Kang CS, Lee CT, Lin HC, Chung SD. Bladder pain syndrome/interstitial cystitis increase the risk of coronary heart disease. Neurourol Urodyn. 2013;33(5):511–5.PubMedCrossRef
58.
Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief 2020(364):1–8.
59.
Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105–14.PubMedCrossRef
60.
Chen J, Zhang H, Niu D, Li H, Wei K, Zhang L, Yin S, Liu L, Zhang X, Zhang M, et al. The risk factors related to the severity of pain in patients with chronic Prostatitis/Chronic Pelvic Pain Syndrome. BMC Urol. 2020;20(1):154.PubMedPubMedCentralCrossRef
61.
Chobufo MD, Gayam V, Soluny J, Rahman EU, Enoru S, Foryoung JB, Agbor VN, Dufresne A, Nfor T. Prevalence and control rates of hypertension in the USA: 2017–2018. Int J Cardiol Hypertens. 2021;6:100044.CrossRef
62.
Navarro-Ledesma S, Gonzalez-Munoz A, Garcia Rios MC, de la Serna D, Pruimboom L. Circadian variation of blood pressure in patients with Chronic Musculoskeletal Pain: a cross-sectional study. Int J Environ Res Public Health 2022, 19(11).
63.
64.
Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC. Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008;71(2):261–6.PubMedCrossRef
65.
Shaqura M, Li L, Mohamed DM, Li X, Treskatsch S, Buhrmann C, Shakibaei M, Beyer A, Mousa SA, Schafer M. Neuronal aldosterone elicits a distinct genomic response in pain signaling molecules contributing to inflammatory pain. J Neuroinflammation. 2020;17(1):183.PubMedPubMedCentralCrossRef
66.
Bali A, Singh N, Jaggi AS. Renin-angiotensin system in pain: existing in a double life? J Renin Angiotensin Aldosterone Syst. 2014;15(4):329–40.PubMedCrossRef
Metadata
Title
Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data
Authors
Rosalynn R.Z. Conic
Terrie Vasilopoulos
Karthik Devulapally
Rene Przkora
Andrew Dubin
Kimberly T. Sibille
Aaron D. Mickle
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2024
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-024-01407-w

Other articles of this Issue 1/2024

BMC Urology 1/2024 Go to the issue

Correction

Correction: MicroRNA-148a-3p in pericyte-derived extracellular vesicles improves erectile function in diabetic mice by promoting cavernous neurovascular regeneration

Research

Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial

Research

Feasibility of outpatient daycase local anaesthestic Rezūm™ without sedation

Research

Forgotten ureteral stents: a systematic review of literature

Research

Risk factors for postoperative fever after laparoscopic adrenalectomy focusing on hormones produced: a case control study

Research

The association between hepatitis B virus and semen quality: a systematic review and meta-analysis